New insider activity at Supernus Pharmaceuticals ( (SUPN) ) has taken place on September 8, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
President & CEO Jack Khattar has recently sold 55,578 shares of Supernus Pharmaceuticals stock, amounting to a significant transaction valued at $2,557,143.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals demonstrates strong financial health and technical momentum, supported by strategic acquisitions. However, high valuation and patent challenges pose risks. The company’s robust cash flow and operational efficiency are key strengths, but attention to revenue growth and cost management is crucial for sustaining long-term performance.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
YTD Price Performance: 26.27%
Average Trading Volume: 831,614
Technical Sentiment Signal: Buy
Current Market Cap: $2.58B